Abstract
Dysregulation of glutamate neurotransmission has been implicated in schizophrenia primarily because antagonists of the nmethyl- d-aspartate (NMDA) subtype of glutamate receptors exacerbate preexisting symptoms of schizophrenia in patients and produce behavioral disruptions that resemble some symptoms of schizophrenia in healthy individuals. Given this, NMDA receptor antagonists have been used extensively to model aspects of the disease in laboratory animals and have provided a useful preclinical tool for testing novel treatment strategies. More recent genetic and postmortem findings have implicated proteins other than the NMDA receptor in the pathophysiology of schizophrenia which play a role in regulation of the glutamate synapse. Animal models developed based on these findings have the potential of increasing our mechanistic understanding of the disease. Here we review some of the pertinent literature related to pharmacological and genetic animal models of glutamate dysfunction in schizophrenia.
Keywords: NMDA, DISC1, phencyclidine, antipsychotic drugs, metabotropic glutamate receptors, glutamate neurotransmission, glutamate synapse, genetic animal models, schizophrenia, auditory hallucinations
Current Pharmaceutical Design
Title:Glutamatergic Animal Models of Schizophrenia
Volume: 18 Issue: 12
Author(s): Corina Bondi, Marguerite Matthews, Bita Moghaddam
Affiliation:
Keywords: NMDA, DISC1, phencyclidine, antipsychotic drugs, metabotropic glutamate receptors, glutamate neurotransmission, glutamate synapse, genetic animal models, schizophrenia, auditory hallucinations
Abstract: Dysregulation of glutamate neurotransmission has been implicated in schizophrenia primarily because antagonists of the nmethyl- d-aspartate (NMDA) subtype of glutamate receptors exacerbate preexisting symptoms of schizophrenia in patients and produce behavioral disruptions that resemble some symptoms of schizophrenia in healthy individuals. Given this, NMDA receptor antagonists have been used extensively to model aspects of the disease in laboratory animals and have provided a useful preclinical tool for testing novel treatment strategies. More recent genetic and postmortem findings have implicated proteins other than the NMDA receptor in the pathophysiology of schizophrenia which play a role in regulation of the glutamate synapse. Animal models developed based on these findings have the potential of increasing our mechanistic understanding of the disease. Here we review some of the pertinent literature related to pharmacological and genetic animal models of glutamate dysfunction in schizophrenia.
Export Options
About this article
Cite this article as:
Corina Bondi, Marguerite Matthews, Bita Moghaddam , Glutamatergic Animal Models of Schizophrenia , Current Pharmaceutical Design 2012; 18 (12) . https://dx.doi.org/10.2174/138161212799958576
DOI https://dx.doi.org/10.2174/138161212799958576 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Fish Oil Fatty Acids as Cardiovascular Drugs
Current Vascular Pharmacology Fetal Origins of Cardiovascular Disease
Current Cardiology Reviews Metabolic Action of Thyroid Hormones: Insights from Functional and Proteomic Studies
Current Proteomics Ginkgo Biloba Extract (EGb 761) in Alzheimers Disease: Is there Any Evidence?
Current Alzheimer Research Colloid Update
Current Pharmaceutical Design Traditional Cardiovascular Risk Factors in Adolescents with Type 1 Diabetes Mellitus
Current Diabetes Reviews Editorial [Hot Topic Cardiovascular and Metabolic Diseases: from Mechanisms to Novel Therapeutical Implications Guest Editors: Attila Borbély and Pawel Petkow Dimitrow]
Current Pharmaceutical Biotechnology Editorial [ Has the Time Come for a New Definition of Microalbuminuria? ]
Current Vascular Pharmacology Emerging Concepts on Inhibitors of Indoleamine 2,3-Dioxygenase in Rheumatic Diseases
Current Medicinal Chemistry Lipoproteins in Atherosclerosis Process
Current Medicinal Chemistry Preface: Vitamin D and QT Interval in Epilepsy: More than an Association?
Current Clinical Pharmacology Role of Insulin in Glucose-Stimulated Insulin Secretion in Beta Cells
Current Diabetes Reviews Catestatin: A Master Regulator of Cardiovascular Functions
Current Medicinal Chemistry Why are People with “Poor Lung Function” At Increased Atherothrombotic Risk?A Critical Review with Potential Therapeutic Indications
Current Vascular Pharmacology Emerging Role for Antioxidant Therapy in Protection Against Diabetic Cardiac Complications: Experimental and Clinical Evidence for Utilization of Classic and New Antioxidants
Current Cardiology Reviews New Strategies and Drugs in the Treatment of Hypertension: Monotherapy or Combination?
Recent Patents on Cardiovascular Drug Discovery Current Pharmacologic Management of Pediatric Heart Failure in Congenital Heart Disease
Current Vascular Pharmacology Emerging Role for RBM20 and its Splicing Substrates in Cardiac Function and Heart Failure
Current Pharmaceutical Design Clozapine Safety, 40 Years Later
Current Drug Safety Comparison Among Aerobic Exercise and Other Types of Interventions to Treat Depression: A Systematic Review
CNS & Neurological Disorders - Drug Targets